Data updated: Jun 28, 2026
Epilepsy Clinical Trial Landscape
Epilepsy is being studied across 466 clinical trials registered since 2008, with 79 programs currently active. The competitive pipeline includes 28 active Phase 3 trials, 27 active Phase 2 trials, and 14 active Phase 1 trials.
Top industry sponsors include Praxis Precision Medicines, UCB Biopharma SRL, Biohaven Therapeutics Ltd..
Trial activity
79 active / 466 total since 2008
Active by phase 28 Ph3 / 170 27 Ph2 / 141 14 Ph1 / 80 10 Ph4 / 75
Sponsor activity
Who is running trials now — green active, blue completed, red failed/terminated.
Sorted by active Active Done Failed
Praxis Precision Medicines 5 0 0
UCB Biopharma SRL 3 5 5
Biohaven Therapeutics Ltd. 3 0 1
Rapport Therapeutics Inc. 3 0 0
SK Life Science, Inc. 2 9 0
Xenon Pharmaceuticals Inc. 2 0 2
Neurona Therapeutics 2 0 0
NeuroPace 2 0 0
Actio Biosciences, Inc. 2 0 0
Shanghai Zhimeng Biopharma, Inc. 2 0 0
Ono Pharmaceutical Co., Ltd. 2 0 0
Supernus Pharmaceuticals, Inc. 1 4 0
NeuroPro Therapeutics, Inc. 1 3 0
Shanghai UniXell Biotechnology Co., Ltd 1 0 0
Zogenix, Inc. 1 0 0
How the field has grown
New-trial starts peaked in 2018 (37 registered); 2025 saw 21. The right-hand chart shows median Phase 3 enrollment by start year — the number in parentheses is that year's Phase 3 trial count (61 in total), so single-trial years (and years with no Phase 3 starts) are obvious. Both are by trial start date; the current year is partial.
New trials started by year
2016 21
2017 24
2018 37
2019 13
2020 10
2021 21
2022 24
2023 12
2024 31
2025 21
2026 12
TheraRadar.com
Median Phase 3 enrollment by start year
2016 (6) 156
2017 (4) 155
2018 (5) 116
2019 (5) 20
2020 (3) 48
2021 (8) 39
2022 (9) 88
2023 (3) 312
2024 (6) 175
2025 (6) 104
2026 (6) 306
TheraRadar.com
Full trial pipeline
Every active and completed trial across Phase 1–4, with enrollment analytics. Sortable, filterable, exportable with Pro.
NCT07281027 NOT YET RECRUITING
COMparison Between Anakinra and Tocilizumab in NORSE - "COMBAT-NORSE"
Yale University n=438
NCT07563881 RECRUITING
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1
Rapport Therapeutics Inc. n=333
NCT06132893 RECRUITING
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
Biohaven Therapeutics Ltd. n=390
NCT05064878 ACTIVE NOT RECRUITING
A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder.
Zogenix, Inc. n=87
NCT06309966 RECRUITING
Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
Biohaven Therapeutics Ltd. n=390
NCT06315322 RECRUITING
A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
UCB Biopharma SRL n=120
NCT05718817 ENROLLING BY INVITATION
An Open-label Study of XEN1101 in Epilepsy
Xenon Pharmaceuticals Inc. n=880
NCT05067634 ACTIVE NOT RECRUITING
Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures
SK Life Science, Inc. n=140
NCT07505004 RECRUITING
Double-blind, Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures
Praxis Precision Medicines n=300
NCT05135091 RECRUITING
Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))
Neurona Therapeutics n=88
NCT04666610 ACTIVE NOT RECRUITING
A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
UCB Biopharma SRL n=153
NCT07377032 RECRUITING
TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
Meyer Children's Hospital IRCCS n=40
NCT07234695 RECRUITING
LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau n=120
NCT07287163 ENROLLING BY INVITATION
Clinical Trial of Vormatrigine in Adult Patients With Epilepsy
Praxis Precision Medicines n=700
NCT07165262 ACTIVE NOT RECRUITING
Effect of Different Anesthetic Drugs on Electrocorticography (ECOG).
Children's Cancer Hospital Egypt 57357 n=88
NCT04715646 RECRUITING
A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures
UCB Biopharma SRL n=70
NCT06579573 RECRUITING
ONO-2017 Study Japanese Patients With Primary Generalized Tonic Clonic Seizures.
Ono Pharmaceutical Co., Ltd. n=15
NCT06999902 RECRUITING
Double-blind, Randomized Trial of PRAX-628 in Adults With Focal Seizures to Evaluate Efficacy and Safety (POWER1)
Praxis Precision Medicines n=230
NCT06262594 RECRUITING
Lemborexant Treatment of Insomnia Linked to Epilepsy
University of Manitoba n=26
NCT07594158 RECRUITING
A Study to Evaluate the Safety, Efficacy, and PK of ONO-2017 in Japanese Patients With POS 2 to 17 Year Olds
Ono Pharmaceutical Co., Ltd. n=20
NCT07594119 RECRUITING
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures
Rapport Therapeutics Inc. n=312
NCT07604350 NOT YET RECRUITING
Edaravone Dexborneol for Post-Stroke Epilepsy
First Affiliated Hospital of Wenzhou Medical University n=160
NCT07668856 RECRUITING
Cannabidiol as add-on Therapy for Children With Refractory Epilepsy (CBD-uN1que), a High-quality Individualized Approach: a Series of N-of-1 Trials
UMC Utrecht n=50
NCT07563634 COMPLETED
Long-term Safety and Efficacy of Adjunctive Brivaracetam in Chinese Patients With Uncontrolled Focal Epilepsy
Jiangxi Qingfeng Pharmaceutical Co. Ltd. n=141
NCT01345058 COMPLETED
Add on Lacosamide Versus High Dose Monotherapy
Brigham and Women's Hospital n=56
NCT04378075 TERMINATED
A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy
PTC Therapeutics n=68
NCT06425159 TERMINATED
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures
Biohaven Therapeutics Ltd. n=27
NCT03961568 COMPLETED
Cenobamate Open-Label Extension Study for YKP3089C025
SK Life Science, Inc. n=147
NCT04485104 TERMINATED
Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures
Jazz Pharmaceuticals n=3
NCT05109234 COMPLETED
A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
UCB Biopharma SRL n=84
NCT01364597 COMPLETED
Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy
UCB Pharma SA n=257
NCT03083665 COMPLETED
A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy
UCB Biopharma SRL n=449
NCT02332447 COMPLETED
Efficacy of Naloxone in Reducing Postictal Central Respiratory Dysfunction in Patients With Epilepsy
Hospices Civils de Lyon n=485
NCT05439876 COMPLETED
Getting SMART for Pediatric Epilepsy
National Taiwan University Hospital n=147
NCT04627285 COMPLETED
A Study to Test the Long-term Use of Oral Lacosamide in Pediatric Study Participants Who Completed NCT01964560 (EP0034) or NCT00938912 (SP848) and Received Lacosamide Treatment
UCB Biopharma SRL n=48
NCT02348073 COMPLETED
Efficacy of Phosphatidylserine Enriched With n-3 PUFA Supplementation on ADHD in Children With Epilepsy
Hospices Civils de Lyon n=77
NCT03250377 COMPLETED
A Study to Test the Safety/ Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization
UCB Biopharma SRL n=207
NCT03678753 COMPLETED
Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures
SK Life Science, Inc. n=169
NCT02201251 COMPLETED
A Study to Investigate the Safety of the Drugs Topiramate and Levetiracetam in Treating Children Recently Diagnosed With Epilepsy
Janssen Research & Development, LLC n=63
NCT01228747 COMPLETED
A Double-blind, Placebo-controlled Study of Levetiracetam in Epilepsy Patients With Generalized Tonic-clonic Seizures (Except Partial Seizures Evolving to Secondarily Generalized Seizures)
UCB Japan Co. Ltd. n=361
NCT04912856 TERMINATED
An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE
Xenon Pharmaceuticals Inc. n=8
NCT03790137 COMPLETED
Treatment of Sunflower Syndrome With ZX008 (Fenfluramine Hydrochloride) in Children and Young Adults (Ages 4-25).
Elizabeth Anne Thiele n=20
NCT04639310 TERMINATED
XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy
Xenon Pharmaceuticals Inc. n=8
NCT03340064 COMPLETED
A Study of Levetiracetam as Monotherapy or Adjunctive Treatment of Partial Seizures in Pediatric Epileptic Subjects Ranging From 1 Month to Less Than 4 Years of Age
UCB Japan Co. Ltd. n=38
NCT02535091 COMPLETED
Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
SK Life Science, Inc. n=1,345
NCT05297695 COMPLETED
Helicobacter Pylori Eradication Therapy for Epileptic Children
Sohag University n=126
NCT02408549 COMPLETED
Safety and Efficacy of Lacosamide as Additional Therapy in Patients Suffering From Epileptic Tonic-Clonic Seizures
UCB BIOSCIENCES, Inc. n=239
NCT04320940 TERMINATED
Efficacy and Safety of Intravenous Phenobarbital in Neonatal Seizures
NEMA Research, Inc. n=4
NCT02682927 COMPLETED
A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) in Children and Young Adults With Dravet Syndrome
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc. n=262
NCT02519439 TERMINATED
A Two-year Open-label Extension Study of Ganaxolone in Patients With Drug-resistant Partial-onset Seizures
Marinus Pharmaceuticals n=26
NCT02582866 COMPLETED
A Clinical Study to Investigate the Long-term Use of Lacosamide as Monotherapy in Subjects Who Completed Study SP0994
UCB Biopharma S.P.R.L. n=106
NCT02710890 COMPLETED
Study to Investigate Safety and Tolerability of Intravenous Lacosamide in Children.
UCB BIOSCIENCES, Inc. n=103
NCT01963208 COMPLETED
Phase 3 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures and Open-label Extension
Marinus Pharmaceuticals n=405
NCT01769092 TERMINATED
Clinical Trial of the Effects of DHA in the Treatment of Seizure Disorders
The Canadian College of Naturopathic Medicine n=6
NCT01529034 TERMINATED
Study to Evaluate the Long-term Safety and Tolerability of USL261 in Patients With Seizure Clusters
UCB Biopharma S.P.R.L. n=175
NCT03739840 TERMINATED
A Study to Test the Efficacy and Safety of Padsevonil as Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy
UCB Biopharma SRL n=232
NCT01964560 COMPLETED
A Clinical Study to Investigate the Efficacy and Safety of Lacosamide as an Add on Therapy in Children With Epilepsy With Partial-onset Seizures
UCB BIOSCIENCES, Inc. n=540
NCT02224560 COMPLETED
Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults
Jazz Pharmaceuticals n=225
NCT02091375 COMPLETED
Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1)
Jazz Pharmaceuticals n=120
NCT02224690 COMPLETED
A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults
Jazz Pharmaceuticals n=171
NCT02224703 COMPLETED
GWPCARE2 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome
Jazz Pharmaceuticals n=199
NCT01261325 COMPLETED
Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures
UCB Pharma n=768
NCT02076698 COMPLETED
Deep Brain Stimulation of the Anterior Nucleus of the Thalamus in Epilepsy
University Hospital, Grenoble n=62
NCT02224573 COMPLETED
An Open Label Extension Study of Cannabidiol (GWP42003-P) in Children and Adults With Dravet or Lennox-Gastaut Syndromes
GW Research Ltd n=681
NCT03536845 COMPLETED
Vitamin D Supplementation to Prevent Vitamin D Deficiency for Children With Epilepsy
King Saud University n=116
NCT01832038 COMPLETED
Study to Evaluate the Safety, Tolerability, and Efficacy of Long-term Adjunctive Therapy With Lacosamide in Adults With Partial-onset Seizures
UCB Pharma SA n=473
NCT01339559 COMPLETED
Brivaracetam Safety and Efficacy Follow-up Study in Subjects With Epilepsy
UCB BIOSCIENCES, Inc. n=767
NCT03428360 COMPLETED
Safety and Tolerability Study of Diazepam Buccal Film (DBF) in Subjects With Epilepsy
Aquestive Therapeutics n=149
NCT02477839 COMPLETED
Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects ≥1 Month to <4 Years With Partial-onset Seizures
UCB BIOSCIENCES, Inc. n=255
NCT03115489 WITHDRAWN
Efficacy of Ketamine Infusion Compared With Traditional Anti-epileptic Agents in Refractory Status Epilepticus
University of Alabama at Birmingham
NCT00988429 COMPLETED
Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures
Bial - Portela C S.A. n=653
NCT03685630 COMPLETED
A Study to Evaluate the Safety and Tolerability of Intravenous Brivaracetam (BRV) as Replacement for Oral Brivaracetam in Japanese Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization
UCB Biopharma S.P.R.L. n=10
NCT01243177 COMPLETED
Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older
UCB BIOSCIENCES GmbH n=888
NCT00596466 COMPLETED
Extension Study Of Long-Term Safety And Efficacy Of Pregabalin As Monotherapy (Lyrica) In Patients With Partial Seizures
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. n=75
NCT01262677 COMPLETED
Once-A-Day Pregabalin For Partial Seizures
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. n=325
NCT01389596 COMPLETED
A Study of the Efficacy and Safety of Pregabalin as Add-On Therapy for Partial Onset Seizures in Children Ages 4-16 Years
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. n=295
NCT01463306 COMPLETED
A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. n=605
NCT02408523 COMPLETED
A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications
UCB BIOSCIENCES, Inc. n=242
NCT01668654 TERMINATED
Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS
GlaxoSmithKline n=4
NCT01981447 COMPLETED
IV Lacosamide: The Safety of Intravenous Lacosamide
Le Bonheur Children's Hospital n=40
NCT03808935 TERMINATED
Cannabis Extract in Refractory Epilepsy Study
The Epilepsy Research Program of the Ontario Brain Institute n=17
NCT01336621 COMPLETED
Long-Term Safety Study of Retigabine Immediate Release (IR) as Adjunctive Therapy in the Treatment of Adults With Partial-Onset Seizures (POS)
GlaxoSmithKline n=98
NCT01777139 COMPLETED
A Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults With Partial Onset Seizures
GlaxoSmithKline n=30
NCT00699972 COMPLETED
Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
Eisai Inc. n=390
NCT02697292 TERMINATED
IVIG in Patients With VGKC Ab Associated Autoimmune Epilepsy
Mayo Clinic n=17
NCT02124564 COMPLETED
A Trial to Evaluate the Long Term Safety and Tolerability of Lacosamide Taken as Monotherapy in Adults With Partial-onset Seizures
UCB Japan Co. Ltd. n=19
NCT01999777 COMPLETED
Study to Evaluate the Safety and Efficacy of USL261 in Patients With Increased Bouts of Seizure Activity in the EMU
UCB Biopharma S.P.R.L. n=62
NCT02161185 TERMINATED
A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters
UCB Biopharma S.P.R.L. n=7
NCT01390220 TERMINATED
Study to Evaluate the Safety and Efficacy of USL261 (Intranasal Midazolam) in Patients With Seizure Clusters
UCB Biopharma S.P.R.L. n=292
NCT03602118 WITHDRAWN
Study to Evaluate Phenobarbital Sodium Injection for the Treatment of Neonatal Seizures
PharPoint Research, Inc.
NCT03580707 COMPLETED
Does BRV Have Faster Onset Time & Greater Effect Than LEV in Epilepsy Pts Using PPR Pharmacodynamic Efficacy Endpoint
Rosenfeld, William E., M.D. n=16
NCT00836836 COMPLETED
Modified Atkins Diet in Childhood Epilepsy
All India Institute of Medical Sciences n=96
NCT01880333 COMPLETED
Evaluation of the Modified Atkins Diet in Young Children With Refractory Epilepsy
Lady Hardinge Medical College n=31
NCT01899898 COMPLETED
Efficacy of a Simplified Modified Atkins Diet in Children With Refractory Epilepsy
Lady Hardinge Medical College n=81
NCT02484001 COMPLETED
Eslicarbazepine Acetate (BIA 2-093) as Monotherapy in Patients With Newly Diagnosed Partial-onset Seizures
Bial - Portela C S.A. n=206
NCT01870024 COMPLETED
Comparison Between Lorazepam, Clonazepam and Clonazepam + Fosphenytoin for the Treatment of Out-of-hospital Generalized Status Epilepticus
Assistance Publique - Hôpitaux de Paris n=434
NCT01648101 TERMINATED
Assessment of the Efficacy and Safety of 2 Doses of Retigabine Immediate Release (900 mg/Day and 600 mg/Day) Used as Adjunctive Therapy in Adult Asian Subjects With Drug-resistant Partial-onset Seizures
GlaxoSmithKline n=76
NCT01921205 COMPLETED
Study to Investigate Lacosamide as Add-on Therapy in Subjects ≥4 Years to <17 Years of Age With Partial Onset Seizures
UCB Pharma n=404
NCT01465997 COMPLETED
Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older
UCB BIOSCIENCES GmbH n=551
NCT01484977 COMPLETED
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
UCB Pharma n=120
NCT00530855 COMPLETED
Trial to Assess Long-term Lacosamide (LCM) Monotherapy Use and Safety of LCM Monotherapy and Adjunctive Therapy for Partial-onset Seizures
UCB Pharma n=322
NCT00910247 COMPLETED
Eslicarbazepine Acetate Monotherapy Long Term Study
Sumitomo Pharma America, Inc. n=274
NCT01728077 COMPLETED
Evaluation of Long-term Safety, and Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects With Epilepsy
UCB Pharma SA n=26
NCT00761774 COMPLETED
An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam
UCB Pharma n=108
NCT01653262 COMPLETED
Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV)
UCB Pharma SA n=29
NCT00698581 TERMINATED
A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures
UCB Pharma n=88
NCT00699283 TERMINATED
A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures
UCB Pharma n=62
NCT01405508 COMPLETED
Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy
UCB Pharma n=105
NCT02427607 COMPLETED
An Open-label Extension Study to Evaluate the Safety and Tolerability of Perampanel (E2007) Administered as an Adjunctive Therapy in Epilepsy Subjects
Eisai Co., Ltd. n=7
NCT02134366 TERMINATED
Clobazam Use in Epilepsia Partialis Continua - Pilot Study
The Cooper Health System n=7
NCT01370044 TERMINATED
Carbon Dioxide (Carbogen) for the Treatment of Febrile Seizures
Charite University, Berlin, Germany n=96
NCT03108729 WITHDRAWN
A Pediatric Drug Study to Determine the Long-term Safety and Tolerability in Children and Adolescents (4-17 Years in Age) Taking the Drug
Sumitomo Pharma America, Inc.
NCT01128959 COMPLETED
Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy
Lundbeck LLC n=108
NCT02195661 COMPLETED
The Role of Melatonin in the Effective Attainment of Sleep Electroencephalograms (EEG) in Children
University of Cape Town n=194
NCT01284556 COMPLETED
Evaluation Phenobarbital as Adjunctive Therapy in Participants With Partial Onset Seizures
West-Ward Pharmaceutical n=314
NCT01891890 TERMINATED
Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE)
Emory University n=72
NCT03014752 COMPLETED
Comparison of the Effectiveness of the Outpatient Classical Ketogenic Diet and Modified Atkins Diet on Seizures Frequency, Nutritional Status and Some Biochemical Factors in Children and Adolescents With Intractable Epilepsy
Tehran University of Medical Sciences n=50
NCT02726867 WITHDRAWN
Levetiracetam, Lacosamide and Ketamine as Adjunctive Treatment of Refractory Status Epilepticus
Mid-Atlantic Epilepsy and Sleep Center, LLC
NCT01393743 COMPLETED
A Efficacy and Safety Study of Adjunctive Perampanel in Primary Generalized Tonic Clonic Seizures
Eisai Inc. n=163
NCT01375374 TERMINATED
Hormonal and Lipid Levels in Male Subjects After a Switch From Carbamazepine to Lacosamide
UCB Pharma n=11
NCT02192814 COMPLETED
Open-label Study to Evaluate the Safety and Tolerability of iv Lacosamide in Japanese Adults With Partial-onset Seizures
UCB Japan Co. Ltd. n=9
NCT01710657 COMPLETED
A Trial to Evaluate the Efficacy and Safety of Adjunctive Therapy With Lacosamide in Adults With Partial-Onset Seizures
UCB Pharma SA n=548
NCT01398956 COMPLETED
An Open Label Study of L059 (Levetiracetam) in Japanese Epilepsy Subjects With Generalized Tonic-clonic Seizures
UCB Pharma n=44
NCT01954121 COMPLETED
Open-label, Randomized, Active-controlled Study of LEV Used as Monotherapy in Patients With Partial-Onset Seizures
UCB Pharma SA n=436
NCT01422720 COMPLETED
Safety and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy for Partial Seizures in Elderly Patients
Bial - Portela C S.A. n=72
NCT00908349 COMPLETED
Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy
Supernus Pharmaceuticals, Inc. n=214
NCT01749046 COMPLETED
Remegal Fixed Dose as Adjunctive Therapy in Patients With Partial Seizures
Valexfarm n=224
NCT00692003 TERMINATED
Adjunctive Zonisamide in Primary Generalised Tonic Clonic Seizures
Eisai Limited n=21
NCT01431976 COMPLETED
Clinical Study of Lamotrigine to Treat Newly Diagnosed Typical Absence Seizure in Children and Adolescents
GlaxoSmithKline n=20
NCT01392768 COMPLETED
Efficacy and Safety of Levetiracetam in Partial Seizures Control, With or Without Secondary Generalization
Ache Laboratorios Farmaceuticos S.A. n=126
NCT01091662 COMPLETED
Safety & Efficacy of Eslicarbazepine Monotherapy in Sub.w/Partial Epilepsy Not Well Controlled by Current Antiepileptic
Sumitomo Pharma America, Inc. n=172
NCT01431963 COMPLETED
Clinical Study of Lamotrigine to Treat Newly Diagnosed Epilepsy
GlaxoSmithKline n=70
NCT02569970 COMPLETED
Efficacy of Fluoxetine Against Seizure-induced Central Apneas
Hospices Civils de Lyon n=70
NCT01162460 COMPLETED
Efficacy and Safety of Eslicarbazepine Acetate as Monotherapy for Patients With Newly Diagnosed Partial-onset Seizures
Bial - Portela C S.A. n=815
NCT00524134 TERMINATED
P-glycoprotein Inhibition as Adjunct Treatment for Medically Refractory Epilepsy.
Columbia University n=6
NCT00735397 COMPLETED
Evaluation of the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
Eisai Inc. n=1,218
NCT00866775 COMPLETED
Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs
Sumitomo Pharma America, Inc. n=193
NCT01136954 COMPLETED
A Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Paediatric Partial Onset Seizures (CATZ Extension Study)
Eisai Limited n=144
NCT00700310 COMPLETED
Evaluating Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
Eisai Inc. n=712
NCT01506882 COMPLETED
An Open Label Study of Levetiracetam Monotherapy in Patients With Newly Diagnosed Focal Epilepsy
UCB Japan Co. Ltd. n=71
NCT00693017 TERMINATED
Efficacy and Safety of Adjunctive Zonisamide in Myoclonic Seizures Associated With Idiopathic Generalised Epilepsy
Eisai Limited n=10
NCT00848549 COMPLETED
Assessing The Long-Term Safety And To Explore The Long-Term Efficacy Of Zonisamide As Monotherapy In Newly Diagnosed Partial Seizures
Eisai Inc. n=295
NCT00441285 COMPLETED
Neurocysticercosis: Combined Treatment With Praziquantel (PZQ) and Albendazole (ABZ)
Universidad Peruana Cayetano Heredia n=156
NCT01292837 COMPLETED
A Study of Levetiracetam in Japanese Pediatric Patients With Generalized Tonic-clonic Seizures
UCB Japan Co. Ltd. n=13
NCT01063764 COMPLETED
An Open Label Study of Levetiracetam in Japanese Pediatric Patients With Partial Seizures
UCB Japan Co. Ltd. n=73
NCT01191086 COMPLETED
Open-label Extension Study to Evaluate the Safety of USL255 in Patients With Refractory Partial-onset Seizures
Upsher-Smith Laboratories n=210
NCT01161108 COMPLETED
Trial of Melatonin to Improve Sleep in Children With Epilepsy and Neurodevelopmental Disabilities
The Hospital for Sick Children n=13
NCT01823159 COMPLETED
Cortical Excitability Changes Induced by Retigabine: a Transcranial Magnetic Stimulation Study
University Hospital of Mont-Godinne n=15
NCT01141764 TERMINATED
Cerebral Metabolic Changes Associated With Thalamic Stimulation
The Hospital for Sick Children n=4
NCT01227902 COMPLETED
Study of Retigabine Immediate Release as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults With Partial-Onset Seizures
GlaxoSmithKline n=203
NCT00699582 COMPLETED
To Evaluate The Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
Eisai Inc. n=389
NCT01142193 COMPLETED
Study to Evaluate the Safety and Effectiveness of USL255 in Patients With Refractory Partial-onset Seizures
Upsher-Smith Laboratories n=249
NCT00741559 COMPLETED
Combined Role of Position Emission Tomography (PET) and Magnetoencephalography (MEG) in Nonlesional Epilepsy
The Hospital for Sick Children n=59
NCT00744731 COMPLETED
An Open-Label Extension Study of the Safety and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures
SK Life Science, Inc. n=403
NCT00566254 COMPLETED
Efficacy and Safety of Adjunctive Zonisamide in Paediatric Partial Onset Seizures (CATZ Study)
Eisai Inc. n=207
NCT00740623 COMPLETED
A Study of the Effectiveness, Safety, and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures.
SK Life Science, Inc. n=547
NCT00175851 WITHDRAWN
Open Label Trial to Study the Long-term Safety and Efficacy of Seletracetam for the Treatment of Epilepsy
UCB Pharma
NCT00717431 TERMINATED
A Multicenter Study of Hippocampal Electrical Stimulation (HS, in Mesial Temporal Lobe Epilepsy
University of Calgary n=8
NCT00908453 COMPLETED
The Study of NPC-06 - Investigation of Safety, Efficacy and Pharmacokinetics of Fosphenytoin
Nobelpharma n=40
NCT04557085 COMPLETED
Randomized, Double-blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in POS
SK Life Science, Inc. n=519
Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only